Charlotte McDonagh

Charlotte McDonagh has extensive experience in the biotechnology and pharmaceutical industry. Charlotte is currently the SVP of Biotherapeutics Discovery at Beam Therapeutics, a position they have held since September 2021. Prior to that, they served as the SVP of Development and Translational Sciences at TetraGenetics Inc. from April 2020 to September 2021.

From 2017 to 2020, McDonagh worked at Magenta Therapeutics as the VP and Head of Biotherapeutics. In this role, they led a team focused on transitioning novel Antibody Drug Conjugates from discovery to the clinic. McDonagh's responsibilities included leading capabilities in Antibody Discovery and Engineering, Bioconjugation, and Analytical Sciences.

Before joining Magenta Therapeutics, McDonagh held various roles at Merrimack from 2007 to 2016. Charlotte served as the Vice President of Discovery, leading Early Biologics Discovery programs and providing protein engineering core services. McDonagh also worked as a Director/Senior Director, Therapeutic Project Leader for MM-111, a bispecific antibody oncology drug candidate. Additionally, they held the role of Associate Director, Therapeutic Project Leader and Principal Scientist at Merrimack.

Earlier in their career, McDonagh worked at Seattle Genetics Inc. as a Research Scientist, Senior Research Scientist, and Principal Scientist. In this role, they were responsible for antibody engineering and expression, leading research project teams in preclinical development, and designing and testing novel engineered antibodies and antibody fragments.

McDonagh began their career as a Postdoctoral Fellow at the University of Washington's Department of Pharmacology from 1997 to 2000.

Charlotte McDonagh has a bachelor's degree in Biochemistry from the University of Bristol, UK, which they obtained in 1992. In 1996, they completed their Ph.D. in Biochemistry from the University of Leicester, UK.